Diranersen
investigational drug
Diranersen (INNTooltip International Nonproprietary Name; developmental code names BIIB080, IONIS-MAPTRx, and ISIS-814907) is an antisense oligonucleotide (ASO) against tau which is under development for the treatment of Alzheimer's disease. It is given by intrathecal injection. The drug is under development by Ionis Pharmaceuticals and Biogen. As of July 2026, it is in phase 2 clinical trials for Alzheimer's disease. Diranersen has been found to decrease levels of tau in cerebrospinal fluid by 30 to 65% and was reported to slightly slow cognitive decline, by 26%, in a preliminary phase 2 trial. This degree of slowing is on par with that of existing anti-amyloid antibodies. The drug is one of the most clinically advanced anti-tau drugs under development.
“Diranersen” enters the record as investigational drug. Crown Archives preserves that source wording while asking what Diranersen, investigational and drug can confirm, complicate or overturn.
Why this record matters
“Diranersen” is worth following because a concise public description often conceals a longer documentary argument. Here, Diranersen, investigational and drug provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jul 20, 2026. The linked authority identifier is Q140645874. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2026.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Diranersen”, its source revision and the description used here.
- Expand the search: follow Diranersen primary sources, Diranersen archive and Diranersen research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Diranersen”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Diranersen” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.